Relmada Therapeutics (RLMD) Total Liabilities (2012 - 2026)

Relmada Therapeutics (RLMD) has reported Total Liabilities for 15 consecutive years, with $16.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities rose 217.44% year-over-year to $16.6 million; the TTM figure through Mar 2026 stood at $16.6 million (up 217.44% YoY), while the FY2025 annual figure was $7.5 million, down 27.24% from the prior year.
• Total Liabilities improved to $16.6 million in Q1 2026 per RLMD's latest filing, from $7.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $215.8 million in Q2 2022 and bottomed at $5.2 million in Q2 2025.
• Historically, Total Liabilities has averaged $48.6 million across 5 years, with a median of $12.4 million in 2024.
• Annual changes were most pronounced in 2025 — Total Liabilities tumbled 92.73% — and 2026, when it soared 217.44%.
• Relmada Therapeutics' Total Liabilities stood at $12.5 million in 2022, then retreated by 2.2% to $12.2 million in 2023, then fell by 15.57% to $10.3 million in 2024, then decreased by 27.24% to $7.5 million in 2025, then soared by 121.99% to $16.6 million in 2026.
• Business Quant data shows RLMD's Total Liabilities at $16.6 million in Q1 2026, $7.5 million in Q4 2025, and $5.4 million in Q3 2025.